The FDA has published draft industry guidance for clinical administration of psilocybin. The comment period ends on August 25, 2023 (16 days from now).<p>The existing comments are interesting to read through, but those with information or expertise to contribute on this topic should consider submitting a public comment before August 25, 2023.